What predicts cognitive decline in de novo Parkinson's disease?

Neurobiology of Aging

Volumn 33, Issue 6, 2012, Pages 1127.e11-1127.e20

  Arnaldi, Dario ^a   Campus, Claudio ^b   Ferrara, Michela ^a   Famà, Francesco ^a   Picco, Agnese ^a   De Carli, Fabrizio ^c   Accardo, Jennifer ^a   Brugnolo, Andrea ^a   Sambuceti, Gianmario ^d   Morbelli, Silvia ^d   Nobili, Flavio ^a,d  

^a UNIVERSITY OF GENOA   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Cognitive decline; Dopamine transporter SPECT; Neuropsychological tests; Parkinson's disease; Perfusion SPECT

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GERIATRIC DEPRESSION SCALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN TRANSPORT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERBAL MEMORY;

EID: 84859492737     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.11.028     Document Type: Article

References (61)

1. 2008, RDC-Team, R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0. http://www.R-project.org.
2. Aarsland D., Beyer M.K., Kurz M.W. Dementia in Parkinson's disease. Curr. Opin. Neurol 2008, 21:676-682.
3. Aarsland D., Bronnick K., Williams-Gray C., Weintraub D., Marder K., Kulisevsky J., Burn D., Barone P., Pagonabarraga J., Allcock L., Santangelo G., Foltynie T., Janvin C., Larsen J.P., Barker R.A., Emre M. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010, 75:1062-1069.
4. Alves G., Wentzel-Larsen T., Aarsland D., Larsen J.P. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005, 65:1436-1441.
5. Boccacci P., Bonetto P., Calvini P., Formiconi A.R. A simple model for the efficient correction of collimator blur in 3D SPECT imaging. Inverse Probl 1999, 15:907-930.
6. Bohnen N.I., Albin R.L. The cholinergic system and Parkinson disease. Behav. Brain Res 2011, 221:564-573.
7. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., Mathis C.A., Moore R.Y., DeKosky S.T. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol 2003, 60:1745-1748.
8. Calvini P., Rodriguez G., Inguglia F., Mignone A., Guerra U.P., Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1240-1253.
9. Caviness J.N., Driver-Dunckley E., Connor D.J., Sabbagh M.N., Hentz J.G., Noble B., Evidente V.G., Shill H.A., Adler C.H. Defining mild cognitive impairment in Parkinson's disease. Mov. Disord 2007, 22:1272-1277.
10. Cools R., Altamirano L., D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006, 44:1663-1673.
11. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003, 41:1431-1441.
12. Costa A., Peppe A., Dell'Agnello G., Caltagirone C., Carlesimo G.A. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 2009, 47:1374-1381.
13. Cropley V.L., Fujita M., Innis R.B., Nathan P.J. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol. Psychiatry 2006, 59:898-907.
14. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
15. Djaldetti R., Ziv I., Melamed E. The mystery of motor asymmetry in Parkinson's disease. Lancet Neurol 2006, 5:796-802.
16. Duchesne N., Soucy J.P., Masson H., Chouinard S., Bédard M.A. Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: a single photon emission computed tomography study using 123iodine-beta-CIT in patients on and off levodopa. Clin. Neuropharmacol 2002, 25:216-224.
17. Dujardin K., Defebvre L., Duhamel A., Lecouffe P., Rogelet P., Steinling M., Destée A. Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J. Neurol 2004, 251:1383-1392.
18. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009, 32:548-557.
19. Emre M. What causes mental dysfunction in Parkinson's disease?. Mov. Disord 2003, 18(suppl 6):S63-S71.
20. Faraway J. Linear models with R 2004, CRC Press, Boca Raton, FL, USA.
21. Ferguson L.W., Rajput M.L., Muhajarine N., Shah S.M., Rajput A. Clinical features at first visit and rapid disease progression in Parkinson's disease. Parkinsonism Relat. Disord 2008, 14:431-435.
22. Filippi L., Manni C., Pierantozzi M., Brusa L., Danieli R., Stanzione P., Schillaci O. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl. Med. Commun 2005, 26:421-426.
23. Frank M.J., Claus E.D. Anatomy of a decision: striato-orbitofrontal interactions in reinforcement learning, decision making, and reversal. Psychol. Rev 2006, 113:300-326.
24. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol 1999, 56:33-39.
25. Grahn J.A., Parkinson J.A., Owen A.M. The cognitive functions of the caudate nucleus. Prog. Neurobiol 2008, 86:141-155.
26. Guerra U.P., Poli G.L., Andreoletti M., Nobili F., Inguglia F., Morbelli S., Sestini S., Mazzeo C., Castagnoli A., Calcagni M.L., Varrone A. Creation of a normal database for striatal uptake semi-quantification of 123I-FP-CIT SPECT. Q. J. Nucl. Med. Mol. Imaging 2009, 53(suppl 1):103.
27. Huang C., Mattis P., Perrine K., Brown N., Dhawan V., Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008, 70:1470-1477.
28. Huang C., Mattis P., Tang C., Perrine K., Carbon M., Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007, 34:714-723.
29. Huang C., Tang C., Feigin A., Lesser M., Ma Y., Pourfar M., Dhawan V., Eidelberg D. Changes in network activity with the progression of Parkinson's disease. Brain 2007, 130:1834-1846.
30. Hudson H.M., Larkin R.S. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans. Med. Imaging 1994, 13:601-609.
31. Hughes T.A., Ross H.F., Musa S., Bhattacherjee S., Nathan R.N., Mindham R.H., Spokes E.G. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000, 54:1596-1602.
32. Jokinen P., Brück A., Aalto S., Forsback S., Parkkola R., Rinne J.O. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat. Disord 2009, 15:88-93.
33. Katz S., Downs T.D., Cash H.R., Grotz R.C. Progress in development of the index of ADL. Gerontologist 1970, 10:20-30.
34. Kehagia A.A., Barker R.A., Robbins T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010, 9:1200-1213.
35. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.
36. Lee A.C., Harris J.P., Calvert J.E. Impairments of mental rotation in Parkinson's disease. Neuropsychologia 1998, 36:109-114.
37. Levy G., Jacobs D.M., Tang M.X., Côté L.J., Louis E.D., Alfaro B., Mejia H., Stern Y., Marder K. Memory and executive function impairment predict dementia in Parkinson's disease. Mov. Disord 2002, 17:1221-1226.
38. Lewis S.J., Slabosz A., Robbins T.W., Barker R.A., Owen A.M. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 2005, 43:823-832.
39. Lo R.Y., Tanner C.M., Albers K.B., Leimpeter A.D., Fross R.D., Bernstein A.L., McGuire V., Quesenberry C.P., Nelson L.M., Van Den Eeden S.K. Clinical features in early Parkinson disease and survival. Arch. Neurol 2009, 66:1353-1358.
40. Marié R.M., Barré L., Dupuy B., Viader F., Defer G., Baron J.C. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci. Lett 1999, 260:77-80.
41. Müller U., Wächter T., Barthel H., Reuter M., von Cramon D.Y. Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J. Neural Transm 2000, 107:303-319.
42. Muslimović D., Post B., Speelman J.D., De Haan R.J., Schmand B. Cognitive decline in Parkinson's disease: a prospective longitudinal study. J. Int. Neuropsychol. Soc 2009, 15:426-437.
43. Nobili F., Campus C., Arnaldi D., De Carli F., Cabassi G., Brugnolo A., Dessi B., Morbelli S., Sambuceti G., Abbruzzese G., Rodriguez G. Cognitive-nigrostriatal relationships in de novo, drug-naive Parkinson's disease patients: a [I-123]FP-CIT SPECT study. Mov. Disord 2010, 25:35-43.
44. Nobili F., Abbruzzese G., Morbelli S., Marchese R., Girtler N., Dessi B., Brugnolo A., Canepa C., Drosos G.C., Sambuceti G., Rodriguez G. Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. Mov. Disord 2009, 24:414-421.
45. Nobili F., Arnaldi D., Campus C., Ferrara M., De Carli F., Brugnolo A., Dessi B., Girtler N., Morbelli S., Abruzzese G., Sambuceti G., Rodriguez G. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:2209-2218.
46. Owen A.M., Beksinska M., James M., Leigh P.N., Summers B.A., Marsden C.D., Quinn N.P., Sahakian B.J., Robbins T.W. Visuospatial memory deficits at different stages of Parkinson's disease. Neuropsychologia 1993, 31:627-644.
47. Post B., Muslimovic D., van Geloven N., Speelman J.D., Schmand B., de Haan R.J. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. Mov. Disord 2011, 26:449-456. CARPA-study group.
48. Redgrave P., Rodriguez M., Smith Y., Rodriguez-Oroz M.C., Lehericy S., Bergman H., Agid Y., DeLong M.R., Obeso J.A. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat. Rev. Neurosci 2010, 11:760-772.
49. Relja M., Klepac N. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease. J. Neurol. Sci 2006, 248:251-254.
50. Rinne J.O., Portin R., Ruottinen H., Nurmi E., Bergman J., Haaparanta M., Solin O. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch. Neurol 2000, 57:470-475.
51. Roos R.A., Jongen J.C., van der Velde E.A. Clinical course of patients with idiopathic Parkinson's disease. Mov. Disord 1996, 11:236-242.
52. Sahakian B.J., Morris R.G., Evenden J.L., Heald A., Levy R., Philpot M., Robbins T.W. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain J. Neurol 1988, 111:695-718.
53. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008, 131:1294-1302.
54. Swainson R., SenGupta D., Shetty T., Watkins L.H., Summers B.A., Sahakian B.J., Polkey C.E., Barker R.A., Robbins T.W. Impaired dimensional selection but intact use of reward feedback during visual discrimination learning in Parkinson's disease. Neuropsychologia 2006, 44:1290-1304.
55. Tang C.C., Eidelberg D. Abnormal metabolic brain networks in Parkinson's disease from blackboard to bedside. Prog. Brain Res 2010, 184:161-176.
56. Tang C.C., Poston K.L., Dhawan V., Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J. Neurosci 2010, 30:1049-1056.
57. Tatsch K., Asenbaum S., Bartenstein P., Catafau A., Halldin C., Pilowsky L.S., Pupi A. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur. J. Nucl. Med. Mol. Imaging 2002, 29:BP30-BP35.
58. Tatsch K., Asenbaum S., Bartenstein P., Catafau A., Halldin C., Pilowsky L.S., Pupi A. European Association of Nuclear Medicine procedure guidelines for brain perfusion SPET using (99m)Tc-labelled radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 2002, 29:BP36-BP42.
59. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord 2010, 25:2649-2653.
60. Williams-Gray C.H., Foltynie T., Brayne C.E., Robbins T.W., Barker R.A. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain J. Neurol 2007, 130:1787-1798.
61. Zhao Y.J., Wee H.L., Chan Y.H., Seah S.H., Au W.L., Lau P.N., Pica E.C., Li S.C., Luo N., Tan L.C. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Mov. Disord 2010, 25:702-708.